Article Text

Download PDFPDF

A phase I study of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies or solid tumors
  1. Stephen Ansell1,
  2. Donald Northfelt2,
  3. Ian Flinn3,
  4. Howard Burris3,
  5. Shira Dinner4,
  6. Victor Villalobos4,
  7. Branimir Sikic4,
  8. Lana Pilja5,
  9. Michael Yellin5,
  10. Tibor Keler5 and
  11. Thomas Davis5
  1. Aff1 grid.66875.3a000000040459167XMayo Clinic Rochester MN USA
  2. Aff2 grid.417468.80000000088756339Mayo Clinic Scottsdale AZ USA
  3. Aff3 grid.419513.b0000000404595478Sarah Cannon Research Institute Nashville TN USA
  4. Aff4 grid.168010.e0000000419368956Stanford Cancer Institute Stanford CA USA
  5. Aff5 grid.417695.8Celldex Therapeutics, Inc. Phillipsburg NJ USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts

CD27, a member of the tumor necrosis factor receptor superfamily, is constitutively expressed on the majority of mature T cells, memory B cells, and a subset of NK cells. We previously demonstrated anti-tumor and immunological properties of the fully human anti-CD27 mAb 1F5 (CDX-1127) in murine tumor models of hematologic and solid tumors. A Phase I dose escalation study of CDX-1127 in patients (pts) with recurrent or treatment-refractory B-cell malignancies and select solid tumors is ongoing. CDX-1127 (0.1 to 10 mg/kg IV) is administered as a single-dose with 28-day observation, followed by 4 weekly doses before restaging at Day 85. Up to 4 additional re-treatment cycles (consisting of 4 weekly doses) are permitted in pts with stable disease or tumor response. Dose-escalation in pts with solid tumors has been completed with preliminary results presented in a separate abstract. Flow cytometry and functional immune analysis of peripheral blood lymphocytes from these solid tumor pts showed an increase in expression of activation markers on T cells (HLA-DR), increases in NK cells, decrease in Tregs, and enhanced T cell response to various stimuli in in vitro assays. Tumor shrinkage was also seen. Dose-escalation in pts with hematologic malignancies is ongoing. To date, 13 B-cell lymphoma pts (3 Hodgkin, 3 follicular, 3 marginal zone, 4 diffuse large B-cell) have received 0.1, 0.3, or 1 mg/kg CDX-1127, with no DLT. Treatment-related toxicity, generally Grade 1-2, included fatigue, nausea, decreased appetite and anemia. One pt with Hodgkin lymphoma who had previously progressed following treatment with chemotherapy, autologous stem cell transplant, and brentuximab vedotin had a partial response (PR) with 77% shrinkage in measurable disease; treatment is ongoing. Three additional pts had stable disease (range: 4.5 to 11+ months), including a pt with follicular lymphoma who has completed 3 cycles of therapy and a pt with marginal zone lymphoma with -36% shrinkage in measurable disease. Flow cytometry and functional immune analysis of peripheral blood lymphocytes are being performed to assess the immunomodulatory activity of CDX-1127 in patients with hematological malignancies. Emerging results suggest that weekly dosing of CDX-1127 is well tolerated with promising biological and early clinical activity. In addition, these data position CDX-1127 well for combination therapy with conventional and immunotherapy approaches as demonstrated in preclinical models.